Bristol Myers (BMY) Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Opdivo plus Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma, based on results from the Phase 3 CheckMate -9DW trial. The CHMP opinion will now be reviewed by the European Commission, which has the authority to approve medicines in the European Union
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers’ Breyanzi receives positive CHMP opinion in follicular lymphoma
- GM, Boeing report quarterly results: Morning Buzz
- Bristol Myers price target raised to $65 from $60 at Citi
- Drugmakers modestly raise price on drugs at start of year, WSJ reports
- Unusually active option classes on open January 24th